Deepak Sapra speaks about DRDO’s anti-covid drug 2DG
In a latest development, Emergency use approval has been granted in India for anti – COVID-19 therapeutic application of the key Active Pharmaceutical Ingredient, 2-deoxy-D-glucose ( 2DG) developed by INMAS, a lab of DRDO, in collaboration with Dr. Reddy’s laboratories.
Deepak Sapra, CEO, API and Services, spoke to ANI news on 17th May 2021, and clarified that 2DG is an oral anti-viral drug that can be administered only upon prescription to hospitalized moderate to severe COVID 19 patients as adjunct ( add on ) therapy along with existing standard of care. He said DRDO's anti-COVID 2-DG drug an add-on, not substitute for other medicines. Click here to read the full response.